FDA Guidance on CBD Infused Products May Signal Bottom for Stock Sector


(NEW YORK)–FDA provided some insight on potential rules and frame work regarding CBD infusion in food & beverages at recent Hemp conference.

Lowell Schiller, the Principal Associate Commissioner for Policy at the Food & Drug Administration (FDA) addressed a hemp conference to outline some guidance on how they may regulate CBD infusion into food & beverages. Despite the growth and popularity of CBD oil products, there are regulations and legislations required depending on each state.

In short, they made clear that CBD infusion in food & beverages remains illegal to sell over the counter without approval. Since CBD was labeled as a drug in the past it would have to adhere to clinical trials and safety standards before being allowed to be sold to consumers. Learning about CBD oil and CBD in general, can better help you understand what it is all about and how it can affect you. Luckily there are online resources for those who are interested in learning more about CBD. Companies similar to Daily Marijuana could help give you the knowledge you need to understand CBD and its different uses.

Enforcement May Be Little For Compliant Players

Offhand this sounds really bad for CBD companies, and it is, but there may be some light on the horizon.

You may have been trading CBD stocks over the past few months and thought you bought a stinker of stock, but that wasn’t totally true. What you had was real money sitting on sidelines waiting to see what the FDA would do since they are a federal agency, and override any state laws that currently stand.

But, as we all know, CBD products are already out there in mass, and even if the FDA wanted to crack down on this exploding industry they may not have the manpower to do that.

So what does this mean?

This means although currently, they are saying CBD infused foods & beverages may be illegal, if the stock you are trading isn’t making any outlandish claims that CBD can cure certain diseases, and being conservative on their labeling, then you may be ok.

If the stock is claiming to cure a certain disease in their releases, or on their labels, then you should avoid those plays.

If the company is being more conservative in their claims, or just selling quicksilver scientific cbd or other hemp oils as a supplement, then those are the best ones to be in right now.

Risks Remains, But So Does Value

This time last year CBD and cannabis stocks were wildly overvalued during their epic run into Sept. 2018. But after that bubble burst, and the fear of FDA enforcement set in over the past few months, CBD stocks now offer much more attractive discounts for traders looking for good entry points.

The sure risk remains with FDA stating such products are not currently legal, but their ability to enforce any recalls may be little to none. As a new framework comes into clarity this fall then CBD stocks may offer a reverse play of ‘sell on rumor, and now buy on the news’.

Would you like to get an update and personal outlook on some specific stocks within this sector? Register to our free investor mailing list and tell us which stocks you have specific interest in

Recent CBD Stocks News

Puration, Inc. (OTC: PURA) announced a financial update is scheduled for release on Thursday, August 22, 2019.

The company announced a $4 million revenue target for 2019, and that it has broken $1 million in sales for the 2018 fiscal year. The company demonstrated over a $1 million base annual revenue run rate in Q1 2019. The company also announced a $1.5 million order to produce private-labeled CBD water that represents sales above and beyond its current distribution network sales.

Kali-Extracts, Inc. (OTC:KALY) reminded shareholders they own stock in a Cannabis biopharmaceutical company with GW pharmaceuticals potential.

Frederick Ferri, the CEO of KALY commented, “We are executing on these simple CBD extraction business strategies to sustain our primary biopharmaceutical development objectives. Next week, on Tuesday, when I provide shareholders with the latest updates on our cannabis extract biopharmaceutical developments, it is my intention to remind the market that we are first and foremost a cannabis extraction biopharmaceutical development company with solutions on par with, if not superior to, those of GW Pharmaceuticals.”

LinkRes Pets (OTC:LRSV) is an interesting CBD play as its core focus is on CBD pet supplements, which may place them in better position to ride under any new rules.

The Company announced the pending launch of their Lynks Pet CBD Water product, in conjunction with American Premium Water (OTC:HIPH) for August 29th on www.SingleSeed.com

CBD Stocks to Watch

CVSI CV Sciences
KGKG Kona Gold Solutions
NBEV New Age Beverages
HIPH American Premium Water
CIIX Chineseinvestors.com
MCOA Marijuana Company of America
BKIT Biohemp International
RMHB Rocky Mountain High Brands
RLBD Real Brands

Start Online Video Courses Today!
This is NOT a solicitation to Buy or Sell any security, but rather is for informational purposes only. Content contained herein includes facts, views, opinions, and recommendations of individuals and organizations deemed of interest. Wall Street Newscast (“WSNC”) does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. In Compliance with SEC Rule 17B WSNC was compensated two thousand three hundred dollars for ongoing media services for Link Reservation and American Premium Water, each. WSNC, or its affiliates, may hold a position in above securities from time to time, and thus should be considered a possible conflict of interest when reviewing this report and information. As of the date of this alert, WSNC, or any of its affiliates, held no positions in securities mentioned above. These investments may involve a high degree of risk, thus investors are highly encouraged to consult with a financial advisor before any and all investments.
Safe Harbor Statements:
This website includes statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
High Risk
Small and Micro cap, or ‘penny stocks’, involve a high degree of risk, and we highly encourage investors to consult with a financial advisor before making any and all investment decisions when investing in these type of securities